These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 30238620)

  • 1. Pharmacokinetics, Pharmacodynamics, and Safety of Evocalcet (KHK7580), a Novel Calcimimetic Agent: An Open-Label, Single- and Multiple-Dose, Phase I Trial in Healthy Chinese Subjects.
    He X; Narushima K; Kojima M; Nagai C; Li K
    Drug Des Devel Ther; 2024; 18():567-581. PubMed ID: 38436038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correction to: Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants.
    Sechaud R; Gu H; Rahmanzadeh G; Taylor A; Chiparus O; Sharma GK; Breitschaft A; Menssen HD
    Cancer Chemother Pharmacol; 2024 Mar; ():. PubMed ID: 38438807
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan.
    Shigematsu T; Shimazaki R; Fukagawa M; Akizawa T
    Clin Pharmacol; 2018; 10():101-111. PubMed ID: 30254496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study.
    Akizawa T; Shimazaki R; Fukagawa M;
    PLoS One; 2018; 13(10):e0204896. PubMed ID: 30379826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evocalcet in the management of secondary hyperparathyroidism in dialysis patients.
    Parfrey PS
    Kidney Int; 2018 Oct; 94(4):661-662. PubMed ID: 30243312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphisms associated with fentanyl pharmacokinetics, pharmacodynamics and adverse effects.
    Saiz-Rodríguez M; Ochoa D; Herrador C; Belmonte C; Román M; Alday E; Koller D; Zubiaur P; Mejía G; Hernández-Martínez M; Abad-Santos F
    Basic Clin Pharmacol Toxicol; 2019 Mar; 124(3):321-329. PubMed ID: 30281924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
    Zurth C; Koskinen M; Fricke R; Prien O; Korjamo T; Graudenz K; Denner K; Bairlein M; von Bühler CJ; Wilkinson G; Gieschen H
    Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):747-759. PubMed ID: 31571146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbohydrate intake attenuates post-exercise plasma levels of cytochrome P450-generated oxylipins.
    Nieman DC; Gillitt ND; Chen GY; Zhang Q; Sakaguchi CA; Stephan EH
    PLoS One; 2019; 14(3):e0213676. PubMed ID: 30883596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP genetic variants and toxicity related to anti-tubercular agents: a systematic review and meta-analysis.
    Richardson M; Kirkham J; Dwan K; Sloan DJ; Davies G; Jorgensen AL
    Syst Rev; 2018 Nov; 7(1):204. PubMed ID: 30458875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA methylation of NR3c1 in infancy: Associations between maternal caregiving and infant sex.
    Conradt E; Ostlund B; Guerin D; Armstrong DA; Marsit CJ; Tronick E; LaGasse L; Lester BM
    Infant Ment Health J; 2019 Jul; 40(4):513-522. PubMed ID: 31066465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the Oral Calcimimetics Evocalcet and Cinacalcet in East Asian Patients on Hemodialysis with Secondary Hyperparathyroidism.
    Ni Z; Liang X; Wu CC; Jin K; Kim YL; Lu KC; Chan TM; Fukagawa M; Kinoshita J; Nagai C; Kojima M; Yu X;
    Kidney Int Rep; 2023 Nov; 8(11):2294-2306. PubMed ID: 38025238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions: Research Methods and Applications.
    Sun L; Mi K; Hou Y; Hui T; Zhang L; Tao Y; Liu Z; Huang L
    Metabolites; 2023 Jul; 13(8):. PubMed ID: 37623842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut Microbiota-Mediated Drug-Drug Interaction between Amoxicillin and Aspirin.
    Zhang J; Sun Y; Wang R; Zhang J
    Sci Rep; 2019 Nov; 9(1):16194. PubMed ID: 31700098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism.
    Akizawa T; Ikejiri K; Kondo Y; Endo Y; Fukagawa M
    Ther Apher Dial; 2020 Jun; 24(3):248-257. PubMed ID: 31486206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients.
    Tsuruya K; Shimazaki R; Fukagawa M; Akizawa T;
    Clin Exp Nephrol; 2019 Jun; 23(6):739-748. PubMed ID: 30955188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comment on: Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study.
    Srinivas NR
    Clin Drug Investig; 2019 Jan; 39(1):105-107. PubMed ID: 30632108
    [No Abstract]   [Full Text] [Related]  

  • 17. Assessment of CYP-Mediated Drug Interactions for Evocalcet, a New Calcimimetic Agent, Based on In Vitro Investigations and a Cocktail Study in Humans.
    Narushima K; Maeda H; Shiramoto M; Endo Y; Ohtsuka S; Nakamura H; Nagata Y; Uchimura T; Kannami A; Shimazaki R; Fukagawa M; Akizawa T
    Clin Transl Sci; 2019 Jan; 12(1):20-27. PubMed ID: 30238620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro.
    Kawata T; Tokunaga S; Murai M; Masuda N; Haruyama W; Shoukei Y; Hisada Y; Yanagida T; Miyazaki H; Wada M; Akizawa T; Fukagawa M
    PLoS One; 2018; 13(4):e0195316. PubMed ID: 29614098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients.
    Shigematsu T; Shimazaki R; Fukagawa M; Akizawa T;
    Clin Exp Nephrol; 2019 Feb; 23(2):258-267. PubMed ID: 30159688
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.